There is currently a lack of biological tools to study the replication cycle and pathogenesis of SARS-CoV-2, the etiological agent of COVID-19. Repurposing the existing tools, including antibodies of SARS-CoV, is an effective way to accelerate the development of therapeutics for COVID-19. Here, we extensively characterized antibodies of the SARS-CoV structural proteins for their cross-reactivity, experimental utility, and neutralization of SARS-CoV-2. We assessed a total of 10 antibodies (six for Spike, two for Membrane, and one for Nucleocapsid and Envelope viral protein). We evaluated the utility of these antibodies against SARS-CoV-2 in a variety of assays, including immunofluorescence, ELISA, biolayer interferometry, western blots, and micro-neutralization. Remarkably, a high proportion of the antibodies we tested showed cross-reactivity, indicating a potentially generalizable theme of cross-reactivity between SARS-CoV and SARS-CoV-2 antibodies. These antibodies should help facilitate further research into SARS-CoV-2 basic biology. Moreover, our study provides critical information about the propensity of SARS-CoV antibodies to cross-react with SARS-CoV-2 and highlights its relevance in defining the clinical significance of such antibodies to improve testing and guide the development of novel vaccines and therapeutics.

中文翻译：

---

SARS-CoV结构蛋白抗体对SARS-CoV-2的交叉反应性。

当前缺少生物学工具来研究SARS-CoV-2（COVID-19的病原体）的复制周期和发病机理。重新利用包括SARS-CoV抗体在内的现有工具，是加速COVID-19疗法发展的有效途径。在这里，我们广泛地表征了SARS-CoV结构蛋白的抗体的交叉反应性，实验实用性和中和SARS-CoV-2的能力。我们总共评估了10种抗体（六种用于Spike，两种用于膜，一种用于Nucleocapsid和Envelope病毒蛋白）。我们评估了这些抗SARS-CoV-2抗体在各种测定中的效用，包括免疫荧光，ELISA，生物层干涉测量，蛋白质印迹和微中和。值得注意的是，我们测试的大部分抗体都表现出交叉反应性，表明SARS-CoV和SARS-CoV-2抗体之间可能具有交叉反应性。这些抗体应有助于促进对SARS-CoV-2基本生物学的进一步研究。此外，我们的研究提供了有关SARS-CoV抗体与SARS-CoV-2交叉反应倾向的重要信息，并强调了其在定义此类抗体的临床意义以改善检测和指导新型疫苗和治疗剂开发方面的相关性。